Return to study ST001467 main page
MB Sample ID: SA124428
| Local Sample ID: | BST200_5m_2 |
| Subject ID: | SU001541 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
Select appropriate tab below to view additional metadata details:
Subject:
| Subject ID: | SU001541 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
Factors:
| Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
|---|---|---|---|---|
| BST200_5m_2 | SA124428 | FL015055 | batch2 | Group |
| BST200_5m_2 | SA124428 | FL015055 | BST204 | Treatment |
| BST200_5m_2 | SA124428 | FL015055 | muscle | Sample Source |
Collection:
| Collection ID: | CO001536 |
| Collection Summary: | Mice were randomized into five groups (n = 10 each): untreated, non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group); tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving 5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving 5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells (1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of phosphate-buffered saline were subcutaneously implanted in the right flank of 8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached 100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was assigned and drug administration started for 5-FU and BST204 groups. BST204 (batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50 mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2; 2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable. BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle: days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our study was determined according to IACUC guidelines, which recommend euthanasia with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our study period was limited to day 11. At this point, the change in tumor volumes was up to 810%, and significant cachexia was observed. |
| Sample Type: | Blood (plasma) |
| Collection Location: | muscle |
| Storage Conditions: | -20℃ |
Treatment:
| Treatment ID: | TR001556 |
| Treatment Summary: | Mice were randomized into five groups (n = 10 each): untreated, non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group); tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving 5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving 5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells (1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of phosphate-buffered saline were subcutaneously implanted in the right flank of 8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached 100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was assigned and drug administration started for 5-FU and BST204 groups. BST204 (batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50 mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2; 2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable. BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle: days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our study was determined according to IACUC guidelines, which recommend euthanasia with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our study period was limited to day 11. At this point, the change in tumor volumes was up to 810%, and significant cachexia was observed. |
| Treatment: | 5-FU was injected intraperitoneally in 3-day cycles. BST204 was orally administerd in 5-day cycles. |
| Treatment Compound: | 5-FU, BST204 |
| Treatment Dose: | 5-FU (50 mg/kg), BST204 (100 or 200 mg/kg) |
| Animal Endp Euthanasia: | study period was limited by day 11 |
Sample Preparation:
| Sampleprep ID: | SP001549 |
| Sampleprep Summary: | Metabolites related to glucose-mediated energy metabolism were extracted using LLE. Amino acids and bioamines were also extracted using LLE and underwent chemical derivatization with phenylisothiocyante. |
| Processing Storage Conditions: | 4℃ |
| Extraction Method: | Liquid Liquid Extraction (LLE) |
Combined analysis:
| Analysis ID | AN002443 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Agilent 1290 |
| Column | Zorbax Eclipse XDB-C18 (100 x 2mm) |
| MS Type | ESI |
| MS instrument type | Triple quadrupole |
| MS instrument name | ABI Sciex 5500 QTrap |
| Ion Mode | POSITIVE |
| Units | area ratio |
Chromatography:
| Chromatography ID: | CH001788 |
| Chromatography Summary: | Metabolites related to glucose-mediated metabolites were analyzed with LC-MS/MS (MRM) |
| Instrument Name: | Agilent 1290 |
| Column Name: | Synergi fusion RP (50 x 2mm) |
| Column Temperature: | 23 |
| Flow Gradient: | 0% B for 5 min, 0% to 90% B for 2 min, hold at 90% B for 8 min, 90% to 0% B for 1 min, and then hold at 0% B for 9 min |
| Flow Rate: | 70 μL/min except for minutes 7 to 15, when it was 140 µL/min |
| Internal Standard: | 13C5-glutamine |
| Sample Injection: | 3 uL |
| Solvent A: | 100% water; 5 mM ammonium acetate |
| Solvent B: | 100% acetonitrile; 5 mM ammonium acetate |
| Chromatography Type: | Reversed phase |
| Chromatography ID: | CH001789 |
| Chromatography Summary: | Amino acids and bioamines were analyzed with LC-MS/MS (MRM) |
| Instrument Name: | Agilent 1290 |
| Column Name: | Zorbax Eclipse XDB-C18 (100 x 2mm) |
| Column Temperature: | 50 |
| Flow Gradient: | 0% B for 0.5 min, 0% to 95% B for 5 min, hold at 95% B for 1 min, 95% to 0% B for 0.5 min, then hold at 0% B for 2.5 min |
| Flow Rate: | 500 μL/min |
| Internal Standard: | 13C5-glutamine, serotonine-d4, dopamine-d4, tryptophan-d5, serine-d3, and lysine-d8 |
| Sample Injection: | 3 uL |
| Solvent A: | 100% water; 0.2% formic acid |
| Solvent B: | 100% acetonitrile; 0.2% formic acid |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS002267 |
| Analysis ID: | AN002443 |
| Instrument Name: | ABI Sciex 5500 QTrap |
| Instrument Type: | Triple quadrupole |
| MS Type: | ESI |
| MS Comments: | Amino acids and bioamines MRM mode Analyst 1.52 |
| Ion Mode: | POSITIVE |
